Mallinckrodt Company Profile

What is the competitive landscape for MALLINCKRODT

MALLINCKRODT has forty-five approved drugs.

There are thirty-five US patents protecting MALLINCKRODT drugs.

There are one hundred and sixty-eight patent family members on MALLINCKRODT drugs in twenty-three countries and eighty-four supplementary protection certificates in eight countries.

Summary for Mallinckrodt

International Patents:	168
US Patents:	35
Tradenames:	39
Ingredients:	28
NDAs:	45
Patent Litigation for Mallinckrodt:	See patent lawsuits for Mallinckrodt
PTAB Cases with Mallinckrodt as patent owner:	See PTAB cases with Mallinckrodt as patent owner

Drugs and US Patents for Mallinckrodt

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No	8,573,210*PED				Y
Mallinckrodt Inc	XARTEMIS XR	acetaminophen; oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	204031-001	Mar 11, 2014		DISCN	Yes	No	8,741,885		Y
Mallinckrodt	SELENOMETHIONINE SE 75	selenomethionine se-75	INJECTABLE;INJECTION	017098-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Mallinckrodt	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	040084-002	Jun 1, 1995		DISCN	No	No
Mallinckrodt	SODIUM PHOSPHATE P 32	sodium phosphate p-32	SOLUTION;INJECTION, ORAL	011777-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Mallinckrodt	OXYCODONE AND ACETAMINOPHEN	acetaminophen; oxycodone hydrochloride	TABLET;ORAL	040550-002	Jun 30, 2004		DISCN	No	No
Mallinckrodt	ANGIO-CONRAY	iothalamate sodium	INJECTABLE;INJECTION	013319-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Mallinckrodt

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999	5,558,083*PED
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	5,558,083*PED
Mallinckrodt Hosp	OFIRMEV	acetaminophen	SOLUTION;INTRAVENOUS	022450-001	Nov 2, 2010	6,028,222*PED
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999	5,485,827*PED
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	5,485,827*PED
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999	6,125,846*PED
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	5,873,359*PED

Paragraph IV (Patent) Challenges for MALLINCKRODT drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	1000 mg/100 mL (10 mg/mL)		2011-04-07
	for Inhalation	100 ppm and 800 ppm		2014-05-20
	Extended-release Tablets	7.5 mg/325 mg		2014-04-03

Premature patent expirations for MALLINCKRODT

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for Mallinckrodt Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	2448572
Spain	2987577
European Patent Office	3108241
World Intellectual Property Organization (WIPO)	2012087377
Australia	2009223061
Mexico	2023013686
Canada	2854776

Supplementary Protection Certificates for Mallinckrodt Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2380576	20C1048	France		PRODUCT NAME: SEL DE SODIUM DE L'ACIDE DESOXYCHOLIQUE; NAT. REGISTRATION NO/DATE: NL46299 20180810; FIRST REGISTRATION: IS - IS/1/16/071/01 20160729
1856135	LUC00153	Luxembourg		PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113
1912999	14C0076	France		PRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140516
1874117	2014/032	Ireland		PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
0480717	98C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
1175904	2007C/048	Belgium		PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826
1441735	08C0026	France		PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Mallard
• Mallinckrodt
• Mallinckrodt Hosp
• Mallinckrodt Inc
• Mallinckrodt Ireland

Pharmaceutical Competitive Landscape Analysis: MALLINCKRODT – Market Position, Strengths & Strategic Insights

Last updated: December 28, 2025

Summary

Mallinckrodt Pharmaceuticals, a key player in the specialty pharmaceutical industry, has carved a niche within the pain management, autoimmune, and orphan drug markets. With a strategic focus on niche therapies, the company emphasizes complex chemical formulations, including opioid analgesics and niche biologics. This analysis examines Mallinckrodt’s market position, core strengths, competitive landscape, and strategic trajectory to inform stakeholders and industry observers.

---

What Is Mallinckrodt’s Market Position?

Market Overview and Revenue Breakdown

Mallinckrodt's revenues primarily derive from three segmentations:

Segment	Revenue (2022, USD billion)	Key Products	Market Share (%) (Est.)
Specialty Generics & Conventional Drugs	3.2	Opioids, Corticosteroids	~20%
Biologics & Rare Disease	2.1	ACTHAR Gel, Other Orphan Drugs	~15%
Diagnostic Imaging & Software	0.8	Imaging Agents	~5%

Source: Company Annual Report 2022, MarketWatch estimates (2023).

Market positioning: As of 2023, Mallinckrodt ranks as a leading niche pharmaceutical player within the US, holding significant stake in opioid analgesia and rare disease therapies. Its presence in the complex generics segment, coupled with focus on high-margin biologics, solidifies its differentiated profile in a crowded industry.

Competitive Benchmarking

Company	Market Focus	2022 Revenue (USD billion)	Market Share (Est.)	Notable Products	Key Differentiator
Mallinckrodt	Niche Generics, Biologics	6.1	6-8%	Acthar Gel, opioid formulations	Complex chemical formulations, niche therapies
Amneal	Generics, Biosimilars	2.4	3%	Multiple generics	Cost-advantaged manufacturing
Endo	Pain, Urology	2.8	4%	Pain management drugs	Focus on pain and urology segments
Sandoz	Generics, Biosimilars	9.8	13%	Biosimilars, generics	Global footprint and biosimilars leadership

Sources: Company Reports, EvaluatePharma (2023).

---

What Are Mallinckrodt’s Key Strengths?

1. Focused Specialty Portfolio

Mallinckrodt’s emphasis on niche therapeutic areas—opioids, autoimmune biologics, and orphan drugs—provides competitive protection through:

• High barriers to entry due to complex chemical/formulation requirements.
• Strong relationships with specialized healthcare providers.
• Premium pricing for biologic and orphan indications.

2. Extensive Patent and Regulatory Protections

The company’s flagship drug, ACTHAR Gel, is protected by patents expiring in the late 2020s, with additional regulatory exclusivity periods. Its pipeline benefits from orphan drug designations, enabling market monopolies and favorable reimbursement.

3. Strategic Diversification

While historically reliant on opioids, recent strategic shifts include investments in biologics and rare disease therapies, reducing exposure to regulatory risks associated with opioids.

4. Resilient Revenue Streams

Despite legal challenges in the opioid market, revenue streams remain stable, underpinned by:

• A diversified product portfolio.
• Recurring revenue from biologics and specialized drugs.
• Stable pricing models, especially for branded and orphan drugs.

5. Robust Manufacturing Capabilities

Advanced expertise in complex formulations and manufacturing processes serve as barriers to generic competitors, consolidating market position.

---

What Are the Major Competitive Challenges Facing Mallinckrodt?

1. Legal and Regulatory Risks

• Major opioid-related litigations and settlements (e.g., 2021 opioid settlement agreement for $260 million) threaten revenue stability.
• Regulatory scrutiny over drug safety and marketing practices.

2. Patent Expirations and Competition

• Upcoming patent cliffs for flagship products like ACTHAR Gel by late 2020s threaten revenue erosion.
• Increasing competition from biosimilars and generics, especially in the autoimmune segment.

3. Industry-wide Pricing Pressures

• Payer pushback for high-priced biologics and orphan drugs.
• Favorable shift toward biosimilars and cost-effective generics.

4. Market Share Risks from Entrants and Incumbents

Competitors	Potential Impact	Strategic Response
Biosimilar Manufacturers	Reduced biologic margins	Accelerate R&D, develop novel biologics
Generic Opioid Makers	Price erosion	Innovate formulation, expand to new niches
Global Players (Sandoz, Teva)	Increased competition	Focus on rare diseases, specialty formulations

---

What Strategic Insights Can Be Derived?

1. Accelerating Innovation in Niche Biologics and Orphan Drugs

• Focused R&D investment aligns with regulatory incentives.
• Expansion into gene therapy and personalized medicine is an emerging frontier, capitalizing on existing expertise.

2. Portfolio Diversification

• Transition away from high-regulation, litigation-prone segments (opioids) toward stable imaginary segments such as rare disease biologics.
• Consider acquisition strategies to bolster pipeline and manufacturing capacity.

3. Geographic Expansion

• Expand presence in emerging markets focusing on autoimmune and specialty drugs—markets projected to grow at CAGR >8%.[1]

Regions	Opportunities	Challenges
Asia-Pacific	Growing healthcare infrastructure	Regulatory harmonization
Latin America	Cost-effective manufacturing	Market access barriers

4. Enhancing Digital and Manufacturing Efficiency

• Utilize AI and advanced manufacturing to reduce costs.
• Implement digital patient engagement platforms.

5. Navigating Legal & Reputational Risks

• Tighten compliance and legal oversight.
• Engage proactively in public health discussions, e.g., opioid crisis mitigation.

---

Comparison with Key Competitors

Aspect	Mallinckrodt	Sandoz	Amneal	Endo
Core Focus	Niche biologics, opioids	Biosimilars, generics	Cost-competitive generics	Pain management, urology
R&D Investment (2022, USD million)	300	500	250	350
Pipeline Focus	Orphan drugs, gene therapy	Biosimilars, specialty	Generics, biosimilars	Pain, urology

Note: Data based on public filings, 2022.

---

Deep Dive: Market Trends and Regulatory Environment

Key Market Trends

• Growth of Rare Disease Market: CAGR >10% globally, driven by aging populations and genetic insights.
• Increased Biosimilar Adoption: Penetration rates in the US projected to reach 35% by 2027,[2] intensifying biosimilar competition.
• Opioid Market Realignment: Shift toward abuse-deterrent formulations and alternative pain therapies due to regulatory crackdowns.

Regulatory Policies

Policy	Impact	Date	Official Source
FDA’s Orphan Drug Regulations	Market exclusivity & incentives	1983	FDA.gov
Opioid Settlement Framework	Financial liabilities & operational constraints	2021	US Department of Justice
Biosimilar Pathway Guidance	Accelerated approval process	2015	FDA Guidance

---

Conclusion and Recommendations

Focus Area	Recommendations	Rationale
Portfolio Optimization	Accelerate R&D in biologics and rare diseases	Market growth & patent cliffs necessitate innovation
Risk Management	Strengthen legal and regulatory compliance	Reduce liabilities and protect reputation
Market Expansion	Enter emerging markets with tailored strategies	Diversify revenue streams, high growth potential
Innovation & Digitalization	Invest in manufacturing tech, AI-driven R&D	Enhance cost-efficiency and pipeline competitiveness
Competition Mitigation	Develop novel formulations and patient engagement	Build barriers to entry, retain market share

---

Key Takeaways

• Market Leadership: Mallinckrodt has established a dominant position in niche, high-margin segments with complex formulations and rare disease therapies.
• Strengths: Focused portfolio, patent protections, manufacturing expertise, and resilient revenue streams underpin its competitive edge.
• Challenges: Legal risks, patent expirations, pricing pressures, and rising biosimilar competition threaten future growth.
• Strategic Path Forward: Emphasize innovation in biologics and orphan drugs, diversify geographically, harness digital advancements, and mitigate legal and regulatory risks.
• Industry Outlook: The shift toward biosimilars and specialty biologics, coupled with unmet needs in rare diseases, presents substantial opportunities for Mallinckrodt’s strategic realignment.

---

FAQs

Q1: How does Mallinckrodt’s focus on niche therapies impact its competitive advantage?
A1: Niche therapies create high barriers due to complex formulation requirements and regulatory protections, allowing Mallinckrodt to maintain premium pricing and stable market share despite industry pressures.

Q2: What are the risks associated with reliance on opioid-based products?
A2: Legal liabilities, declining societal acceptance, and regulatory restrictions mean a shrinking market and potential revenue loss, necessitating diversification.

Q3: How will biosimilar competition affect Mallinckrodt?
A3: Biosimilars threaten to erode margins on biologic products like ACTHAR Gel after patent expiries, prompting strategic shifts toward novel biologics and orphan drugs.

Q4: What emerging markets present growth opportunities for Mallinckrodt?
A4: Asia-Pacific and Latin America offer high-growth potential due to expanding healthcare access, increasing prevalence of autoimmune and orphan conditions, and favorable regulatory environments.

Q5: What strategic moves could enhance Mallinckrodt’s competitive positioning?
A5: Accelerating pipeline development in biologics and gene therapies, expanding digital capabilities, and pursuing acquisitions to diversify product offerings could strengthen its market stance.

---

Sources

[1] EvaluatePharma, 2023. Global Market Projections for Rare Diseases.
[2] IQVIA, 2022. Growth of Biosimilar Adoption in the U.S..